type 2 inflammation

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal[...]

By sjmartinez • February 13, 2024

Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study

Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A. Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults[...]

By sjmartinez • October 23, 2023